COVID-19: Govt says AY.1 not a variant of concern

Govt says AY.1 not a variant of concern but Covid appropriate behaviour must be followed
Image: Pexel

The government expressed concern over a new Covid-19 variant, AY.1. As the AY.1 is closely related to Delta variant. AY.1, or B.1.617.2.1, has a mutation, K147N, which has been asssociated with the Beta variant, first identified in South Africa. More importantly, that is linked to high infectivity.

This variant was first identified in March in Europe. Though it’s not a Variant of Concern (VOC). Not much is known about this virus yet. Researchers are studying further about this variant.

Moreover, controlling the chain of transmission remains the only solution to stop the virus spread. For that containment zones, isolation of infected people and adopting Covid-appropriate behaviour are a must.

Ay.1 is the result of the continuous evolution of the Delta variant. India has been reporting a downward trajectory of the COVID-19 cases. The second wave peak has passed and cases have fallen below 1 lakh in the past few days.

AY.1 not a variant of concern but Covid appropriate behaviour is a must

But COVID appropriate behaviour is a must in order to curtail the rise in its spread.

Several states/UTs are also preparing for a possible third wave of Coronavirus infections.

Health experts are warning against any negligence in following the covid appropriate behaviour.

As a country, it is our collective responsibility to keep following COVID-19 norms even after vaccination. The world will only see life back on track once we realise our duties as a citizen first.

Scientists at the CSIR Institute of Genomics and Integrative Biology (IGIB) have made some significant findings of this new variant — AY.1.

It is associated with immune escape properties. This, in turn, renders a pathogen partially or fully resistant to the body’s immune response, vaccines and antibody therapies.

Furthermore, evidence of AY.1 in India comes from Andhra Pradesh, Maharashtra, Telangana and Karnataka.

Novavax in India

To give a further boost to vaccination drive in the country, Novavax is here. The U.S. company has partnered with the Serum Institute of India (SII).

Novavax maintains that it plans to apply for authorisations in the third quarter (July-September) and is on track to manufacture 100 million doses per month by the end of September. So, it will be 150 million doses per month by the end of 2021. Most of these doses will go to low and middle-income countries.

The G7 nations have come ahead to help world nations by giving out vaccine jabs. But it will all be fine only when we from our end begin covid appropriate behaviour practice. Wearing mask, sanitising regularly and avoiding visiting public places unnecessarily will prove to be of immense help in curbing the virus spread.

The world countries are also trying to convince China for a deeper probe into the coronavirus origins. Building a better tomorrow starts with us today.

Several Indian states are reporting a downward trend in coronavirus cases. Therefore, following covid appropriate behaviour remains of utmost importance.

ALSO READ: Sputnik V Vaccine: Availability, Price And Step-By-Step CoWIN Registration Process